Figure 2.
Figure 2. Proposed use of prognostic tests to risk stratify patients with early-stage CLL. / From Shanafelt et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145:435–447 . Reprinted with permission from the American College of Physicians. / 1 Fever, weight loss, night sweats, fatigue NOT due to other cause (see text). / 2 If available at your center. / 3 Less than 2% mutated compared with germline sequence. / 4 Although high ZAP-70 expression may be used to categorize early stage patients as high risk in the future, this assay cannot be recommended for routine clinical use until it can be standardized and shown to have reliable intralaboratory reproducibility.

Proposed use of prognostic tests to risk stratify patients with early-stage CLL.

From

Shanafelt et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med
.
2006
;
145
:
435
–447
. Reprinted with permission from the American College of Physicians.

1 Fever, weight loss, night sweats, fatigue NOT due to other cause (see text).

2 If available at your center.

3 Less than 2% mutated compared with germline sequence.

4 Although high ZAP-70 expression may be used to categorize early stage patients as high risk in the future, this assay cannot be recommended for routine clinical use until it can be standardized and shown to have reliable intralaboratory reproducibility.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal